Muhammad Amir Misbah-ul Qamar, Tahira Sumreen, Andaleeb Khan, Kamil Rehman Butt, Ejaz Ali, Ayesha Rehman.
Comparison of effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors with dipeptidyl peptidase-4 (DPP-4) inhibitors on Hba1c level in type 2 diabetes in Pakistani population.
Pak Armed Forces Med J Jan ;72(1):25-8.

Objective: To compare the effect of SGLT-2 inhibitors with DPP-4 inhibitors as the add on therapy to Metformin on HBA1c level in type 2 diabetes patients in Pakistani population. Study Design: Quasi-experimental study. Place and Duration of Study: Combined Military Hospital Sialkot, Pakistan from Nov to Apr 2020. Methodology: The study population comprised of 300 type-II diabetes patients with poorly controlled diabetes on Metformin managed at Combined Military Hospital Sialkot, Pakistan. Patients were divided into two groups via lottery method. Group A received the SGLT-2 inhibitors at standard dose while group-B received the DPP-4 inhibitors at the usual standard does as recommended by the consultant medical specialist. Values of glycosylated hemoglobin were compared three months after the start of study. Results: Mean age of the patients was 44.31 ± 5.841 years. Mean duration of type 2 diabetes mellitus in the study participants was 4.18 ± 6.369 years. HBA1c after three months of treatment in the SGLT-2 inhibitors-group was 7.01 ± 0.14 mmol/L while in the DPP-4 inhibitors-group was 7.89 ± 0.99 mmol/L. Difference between the two groups was statistically significant (p value <0.01). The result showed SGLT-2 inhibitors as the better option for add on therapy to Metformin as compared to DPP-4 inhibitors. Conclusion: SGLT-2 inhibitors emerged as better option to lower the HBA1c level as compared to DPP-4 inhibitors as the add on therapy to Metformin as there was statistically significant difference in HBA1c levels after three months of therapy in both the groups.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com